IRIS
CARLOMAGNO, FRANCESCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.339
EU - Europa 867
AS - Asia 231
AF - Africa 18
OC - Oceania 2
SA - Sud America 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 2.460
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.293
IT - Italia 454
CN - Cina 195
IE - Irlanda 89
FI - Finlandia 82
UA - Ucraina 78
DE - Germania 61
CA - Canada 46
GB - Regno Unito 31
NL - Olanda 30
SE - Svezia 22
CI - Costa d'Avorio 18
IN - India 14
FR - Francia 9
HK - Hong Kong 6
SG - Singapore 6
PH - Filippine 4
ES - Italia 3
AU - Australia 2
KR - Corea 2
RO - Romania 2
BD - Bangladesh 1
BE - Belgio 1
BO - Bolivia 1
CH - Svizzera 1
CL - Cile 1
DK - Danimarca 1
EU - Europa 1
GR - Grecia 1
IL - Israele 1
JP - Giappone 1
LU - Lussemburgo 1
PL - Polonia 1
TR - Turchia 1
Totale 2.460
Salva come PNG Salva come JPEG
Città #
Chandler 226
Jacksonville 94
Millbury 87
Princeton 83
Napoli 79
Ashburn 72
Naples 60
Nanjing 59
Ottawa 44
Wilmington 38
Boston 35
Beijing 30
Amsterdam 26
Woodbridge 25
Nanchang 22
Des Moines 19
Shenyang 16
Augusta 15
Lawrence 15
Nocera Superiore 15
Salerno 13
Shanghai 13
Falls Church 12
Ann Arbor 11
Boardman 11
Hebei 11
Rome 11
Kunming 10
Waldbuttelbrunn 10
Changsha 9
Kronberg 9
San Mateo 8
Acerra 7
New York 7
Santa Maria Capua Vetere 7
Washington 7
Jiaxing 6
Redwood City 6
Tianjin 6
Fisciano 5
Giugliano in Campania 5
Hangzhou 5
Indiana 5
Little Rock 5
Norwalk 5
Tito 5
Cleveland 4
Dearborn 4
Formia 4
General Trias 4
Hamburg 4
Milan 4
Pozzuoli 4
Pune 4
Casoria 3
Changchun 3
Chicago 3
Genoa 3
London 3
Pescara 3
Portoferraio 3
San Francisco 3
San Nicola 3
Serino 3
Sorrento 3
Afragola 2
Bacoli 2
Barano d'Ischia 2
Battipaglia 2
Bloomsbury 2
Buffalo 2
Cantù 2
Caposele 2
Caserta 2
Castellammare di Stabia 2
Chions 2
Col Cornacchia 2
Cremona 2
Dublin 2
Farmingdale 2
Giugliano In Campania 2
La Canada Flintridge 2
Madrid 2
Melizzano 2
Orange 2
Pinerolo 2
Pomigliano d'Arco 2
Pozzallo 2
San Felice A Cancello 2
Scafati 2
Shenzhen 2
Singapore 2
Somma Vesuviana 2
Sydney 2
Toronto 2
Verona 2
Basel 1
Berlin 1
Bethesda 1
Brussels 1
Totale 1.400
Salva come PNG Salva come JPEG
Nome #
Association between DNA methylation profile and malignancy in follicular-patterned thyroid neoplasms 115
Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase 75
NCOA4 links iron bioavailability to DNA metabolism 52
NCOA4 Deficiency Impairs Systemic Iron Homeostasis 52
Bioisosteric discovery of npa101.3, a second-generation ret/vegfr2 inhibitor optimized for single-agent polypharmacology 50
BAY 43-9006 inhibition of oncogenic RET mutants 49
Activation of the Erk8 mitogen-activated protein (MAP) kinase by RET/PTC3, a constitutively active form of the RET proto-oncogene. 48
Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology 48
The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer 48
BRAF is a therapeutic target in aggressive thyroid carcinoma. 46
The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes 43
The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells. 43
I geni oncosoppressori in "Patologia Generale" IV Ed, Pontieri-Russo-Frati 42
Therapeutic strategies to target the receptor tyrosine kinase AXL in thyroid cancer 42
Attacking cancer with molecularly targeted agents 41
NCOA4 inhibits initiation of DNA replication to maintain genome stability 41
Regulation of p27Kip1 protein levels contributes to mitogenic effects of the RET/PTC kinase in thyroid carcinoma cells. 39
NCOA4 transcriptional coactivator inhibits activation of DNA replication origins. 38
Peroxiredoxin-2: A Novel Regulator of Iron Homeostasis in Ineffective Erythropoiesis 38
Targeted activity of the small molecule kinase inhibitor Pz-1 towards RET and TRK kinases 38
The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affaected by familial medullary thyroid carcinoma. 37
Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application 37
Benzimidazole Analogues and related methods 37
Activation of RET as a dominant transforming gene by germline mutatios of MEN2A and MEN2B 36
Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomas 35
Central role of RET in thyroid cancer 35
POR Campania FESR SATIN 35
NCOA4 Links Iron Bioavailability to DNA Metabolism 34
ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases 32
Receptor- and non-receptor tyrosine kinases induce processing of the amyloid precursor protein: role of the low-density lipoprotein receptor-related protein. 32
Drug insight: Small-molecule inhibitors of protein kinases in the treatment of thyroid cancer. 31
Receptor tyrosine kinases as targets for anticancer therapeutics 31
Basi molecolari delle nuove terapie: inibitori delle protein-chinasi. 31
Ret gene fusions in malignancies of the thyroid and other tissues 31
Mitogenic effects of the up-regulation of minichromosome maintenance proteins in anaplastic thyroid carcinoma 30
Genetic Alterations in differentiated thyroid cancer:what can be expected for gene expression profiling of thyroid carcinomas 30
Different mutations of the RET gene cause different human tumoral diseases. 30
The Insulin Receptor Substrate (IRS)-1 recruits Phosphatidylinositol 3-Kinase to Ret: evidence for a competition between Shc and IRS-1 for the binding to Ret. 28
Cloning of the rat tissue inhibitor of metalloproteinases type 2 (TIMP-2) gene: analysis of its expression in normal and transformed thyroid cells. 28
D898_E901 RET Deletion Is Oncogenic, Responds to Selpercatinib, and Treatment Resistance Can Arise Via RET-Independent Mechanisms 27
Molecular Mechanism of RET in Human Cancer 27
Clinical case seminar: in vivo and in vitro characterization of a novel germline RET mutation associated with low-penetrant nonaggressive familial medullary thyroid carcinoma. 27
Constitutive and AP20187-induced ret activation in photoreceptors does not protect from light-induced damage 26
Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase 26
Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose 26
Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. 24
RET ONCOGENE ACTIVATION IN HUMAN THYROID NEOPLASMS IS RESTRICTED TO THE PAPILLARY CANCER SUBTYPE 24
Growth factor transduction pathways: paradigm of anti-neoplastic targeted therapy 24
Potent mitogenicity of the RET/PTC3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinoma 23
Identification of RET kinase inhibitors as potential new treatment for sporadic and inherited thyroid cancer. 23
POINT MUTATION OF THE RET PROTO-ONCOGENE IN THE TT HUMAN MEDULLARY THYROID CARCINOMA CELL LINE 22
Molecular biology of the MEN2 gene 22
Molecular mechanism of 17-allylamino-17-demethoxygeldanamycin (17-AAG)-induced AXL receptor tyrosine kinase degradation. 22
RET Is a Heat Shock Protein 90 (HSP90) Client Protein and Is Knocked Down upon HSP90 Pharmacological Block. 21
Cloning and molecular characterization of a novel gene strongly induced by the adenovirus E1A gene in rat thyroid cells 21
RET\PTC activation in human thyroid carcinomas 20
Determination of the frequency of the common 657Del5 Nijmegen breakage syndrome mutation in the German population: no association with risk of breast cancer 20
Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2). 18
Iron and ferritin modulate MHC Class i expression and NK cell recognition 18
Molecular targeting of the RET kinase in thyroid cancer 17
Evolutionary conservation of the Eps8 gene and its mapping to human-chromosome 12q23-q24 17
The different RET-activating capability of mutations of cysteine 620 or cysteine 634 correlates with the multiple endocrine neoplasia type 2 disease phenotype. 17
Functional characterization of a novel FGFR1OP-RET rearrangement in hematopoietic malignancies. 17
Identification of two novel RET kinase inhibitors through MCR-based drug discovery: design, synthesis and evaluation 17
Tamoxifen erythroid toxicity revealed by studying the role of nuclear receptor co-activator 4 in erythropoiesis 17
Receptor tyrosine kinase inhibitors in thyroid cancer. 16
Minireview:RET:normal and abnormal functions 16
Frequent RET proto-oncogene mutations in multiple endocrine neoplasia type 2A 16
Comparison of DNA repair protein expression and activities between human fibroblast cell lines with different radiosensitivities 16
RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. 16
The Macrophage Nuclear Receptor Coactivator 4 Counteracts Iron-Deficiency Anemia 16
The pyruvate kinase activator mitapivat reduces hemolysis and improves anemia in a β-thalassemia mouse model 16
Identification of Polo-like kinase 1 as a potential therapeutic target in anaplastic thyroid carcinoma. 15
Identification of tyrosine 806 as a molecular determinant of RET kinase sensitivity to ZD6474 15
Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation 15
Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2) 14
Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer. 14
Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors 13
Constitutive and AP20187-induced Ret activation in photoreceptors does not protect from light-induced damage. 13
NCOA4-mediated ferritinophagy in macrophages is crucial to sustain erythropoiesis in mice 13
The Human Eps15 gene encoding a tyrosine kinase substrate is conserved in evolution and map to 1p31-1p32 12
Molecular heterogeneity of RET loss of function in Hirschsprung's disease 12
Protein kinase Calpha activation by RET: evidence for a negative feedback mechanism controlling RET tyrosine kinase 12
Molecular mechanisms of RET activation in human neoplasia. 12
Involvement of RET oncogene in human tumours: specificity of RET activation to thyroid tumours. 12
Molecular mechanisms of RET activation in human cancer. 11
null 11
Tyrosine 1062 of RET-MEN2A mediates activation of Akt (protein kinase B) and mitogen-activated protein kinase pathways leading to PC12 cell survival 11
Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants. 11
The extent of linkage disequilibrium in four populations with distinct demographic histories 11
Point mutation of the RET proto-oncogene in the TT human medullary thyroid carcinoma cell line. 11
Oncogenic rearrangements driving ionizing radiation-associated human cancer 11
Ret-mediated mitogenesis requires Src kinase activity 10
New therapeutic approaches to treat medullary thyroid carcinoma. 9
Thyroid cancer in 2010: A roadmap for targeted therapies 9
Only the substitution of methionine 918 with a threonine and not with other residues activates RET transforming potential 9
Pros and cons of cellular studies in developing new drugs for thyroid cancers 8
Signalling of the Ret receptor tyrosine kinase through the c-Jun N-terminal Protein Kinases (JNKs): evidence for a divergence of the ERKs and JNKs pathways induced by Ret 8
Mutations in the extracellular domain cause RET loss of function by a dominant negative mechanism 8
Dysfunction of the RET receptor in human cancer 8
Totale 2.601
Salva come PNG Salva come JPEG
Categoria #
all - tutte 10.300
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.300
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201925 0 0 0 0 0 0 0 0 0 8 11 6
2019/2020353 113 7 17 26 32 9 18 7 6 20 47 51
2020/2021286 8 30 23 30 18 47 24 13 20 2 61 10
2021/2022532 8 3 17 3 4 20 19 30 97 32 100 199
2022/2023586 108 44 4 51 75 63 10 51 81 48 39 12
2023/2024392 21 89 56 44 39 51 22 48 16 6 0 0
Totale 2.608